121 related articles for article (PubMed ID: 24316476)
1. Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution.
Vilella A; Tosi G; Grabrucker AM; Ruozi B; Belletti D; Vandelli MA; Boeckers TM; Forni F; Zoli M
J Control Release; 2014 Jan; 174():195-201. PubMed ID: 24316476
[TBL] [Abstract][Full Text] [Related]
2. Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport.
Tosi G; Vilella A; Chhabra R; Schmeisser MJ; Boeckers TM; Ruozi B; Vandelli MA; Forni F; Zoli M; Grabrucker AM
J Control Release; 2014 Mar; 177():96-107. PubMed ID: 24417968
[TBL] [Abstract][Full Text] [Related]
3. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide.
Kirby BP; Pabari R; Chen CN; Al Baharna M; Walsh J; Ramtoola Z
J Pharm Pharmacol; 2013 Oct; 65(10):1473-81. PubMed ID: 24028614
[TBL] [Abstract][Full Text] [Related]
5. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.
Tosi G; Vergoni AV; Ruozi B; Bondioli L; Badiali L; Rivasi F; Costantino L; Forni F; Vandelli MA
J Control Release; 2010 Jul; 145(1):49-57. PubMed ID: 20338201
[TBL] [Abstract][Full Text] [Related]
6. Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain.
Belletti D; Grabrucker AM; Pederzoli F; Menrath I; Vandelli MA; Tosi G; Duskey TJ; Forni F; Ruozi B
Int J Pharm; 2018 May; 543(1-2):300-310. PubMed ID: 29608954
[TBL] [Abstract][Full Text] [Related]
7. Brain-targeted polymeric nanoparticles: in vivo evidence of different routes of administration in rodents.
Tosi G; Ruozi B; Belletti D; Vilella A; Zoli M; Vandelli MA; Forni F
Nanomedicine (Lond); 2013 Sep; 8(9):1373-83. PubMed ID: 23565661
[TBL] [Abstract][Full Text] [Related]
8. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Bortot B; Ruozi B; Dolcetta D; Vandelli MA; Forni F; Severini GM
Curr Med Chem; 2013; 20(17):2212-25. PubMed ID: 23458620
[TBL] [Abstract][Full Text] [Related]
9. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.
Tosi G; Costantino L; Rivasi F; Ruozi B; Leo E; Vergoni AV; Tacchi R; Bertolini A; Vandelli MA; Forni F
J Control Release; 2007 Sep; 122(1):1-9. PubMed ID: 17651855
[TBL] [Abstract][Full Text] [Related]
10. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier.
Chang J; Jallouli Y; Kroubi M; Yuan XB; Feng W; Kang CS; Pu PY; Betbeder D
Int J Pharm; 2009 Sep; 379(2):285-92. PubMed ID: 19416749
[TBL] [Abstract][Full Text] [Related]
11. Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles.
Vilella A; Ruozi B; Belletti D; Pederzoli F; Galliani M; Semeghini V; Forni F; Zoli M; Vandelli MA; Tosi G
Pharmaceutics; 2015 Jun; 7(2):74-89. PubMed ID: 26102358
[TBL] [Abstract][Full Text] [Related]
12. Endocytosis-like uptake of surface-modified drug nanocarriers into giant unilamellar vesicles.
Tahara K; Tadokoro S; Kawashima Y; Hirashima N
Langmuir; 2012 May; 28(18):7114-8. PubMed ID: 22515197
[TBL] [Abstract][Full Text] [Related]
13. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
14. Fabrication and statistical optimization of surface engineered PLGA nanoparticles for naso-brain delivery of ropinirole hydrochloride: in-vitro-ex-vivo studies.
Patil GB; Surana SJ
J Biomater Sci Polym Ed; 2013; 24(15):1740-56. PubMed ID: 23705812
[TBL] [Abstract][Full Text] [Related]
15. Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders.
Carroll RT; Bhatia D; Geldenhuys W; Bhatia R; Miladore N; Bishayee A; Sutariya V
J Drug Target; 2010 Nov; 18(9):665-74. PubMed ID: 20158436
[TBL] [Abstract][Full Text] [Related]
16. NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences.
Tosi G; Bondioli L; Ruozi B; Badiali L; Severini GM; Biffi S; De Vita A; Bortot B; Dolcetta D; Forni F; Vandelli MA
J Neural Transm (Vienna); 2011 Jan; 118(1):145-53. PubMed ID: 20931242
[TBL] [Abstract][Full Text] [Related]
17. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
Wang ZH; Wang ZY; Sun CS; Wang CY; Jiang TY; Wang SL
Biomaterials; 2010 Feb; 31(5):908-15. PubMed ID: 19853292
[TBL] [Abstract][Full Text] [Related]
18. In vitro uptake evaluation in Caco-2 cells and in vivo results in diabetic rats of insulin-loaded PLGA nanoparticles.
Reix N; Parat A; Seyfritz E; Van der Werf R; Epure V; Ebel N; Danicher L; Marchioni E; Jeandidier N; Pinget M; Frère Y; Sigrist S
Int J Pharm; 2012 Nov; 437(1-2):213-20. PubMed ID: 22940208
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells.
Mo L; Hou L; Guo D; Xiao X; Mao P; Yang X
Int J Pharm; 2012 Oct; 436(1-2):815-24. PubMed ID: 22846410
[TBL] [Abstract][Full Text] [Related]
20. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction.
Chang MY; Yang YJ; Chang CH; Tang AC; Liao WY; Cheng FY; Yeh CS; Lai JJ; Stayton PS; Hsieh PC
J Control Release; 2013 Sep; 170(2):287-94. PubMed ID: 23665256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
